Balanitis xerotica obliterans when clobetasol propionate fails to resolve white plaques and induration

This protocol applies to patients with balanitis xerotica obliterans (BXO) whose first-line topical corticosteroid course has not produced the expected lesion clearance — specifically when daily clobetasol propionate ointment to the glans penis and foreskin has not resolved penile white plaques and induration at the 3-month treatment mark.

Previous line — failure condition

Daily topical application of clobetasol propionate ointment to the glans penis and foreskin is the established first-line approach for BXO. This next-line protocol is indicated when resolution of penile white plaques and induration has not been achieved at 3 months of that therapy.

Next-line approach — partial overview

When topical corticosteroid therapy is insufficient, this protocol incorporates systemic oral retinoid therapy or a targeted injectable biologic agent. Each option has a distinct clinical goal at 20 weeks. The complete eligibility criteria, regimen details, and sequencing are available in the full protocol.

Clinical goals

Treatment targets aim for complete resolution of BXO at 20 weeks with one approach, or stable mild disease with the other — depending on the option selected within the protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ijd.14236

TCS are the mainstay of treatment, however, use of acitretin and adalimumab has been documented.

In 2010, a Greek double bind placebo-controlled trial with a cohort of 49 demonstrated complete resolution of BXO in 36% of patients taking acitretin 35 mg daily for 20 weeks.

Lowenstein and Zeichner used intralesional adalimumab, 40 mg biweekly and then 8 weekly, to achieve stable mild disease in a case of recalcitrant BXO.

It was injected subcutaneously at 1 cm intervals around the penile shaft.

View source ↗